Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 105

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 105
---
 ) |
| Net income (loss) attributable to common shareholders                                     |     | $             |  (515,384 | ) |     | $        |  (144,913 | ) |
| Per common share basic and diluted:                                                       |     |               |           |   |     |          |           |   |
| Net loss per common share attributable to Regen Biopharma shareholders, basic and diluted |     | $             |     (0.13 | ) |     | $        |     (0.04 | ) |
| Number of weighted average shares - basic and diluted                                     |     |               | 4,110,265 |   |     |          | 3,596,027 |   |

<div align='center'>The Accompanying Notes are an Integral Part of These Financial
Statements

All stock amounts have been retroactively adjusted to reflect
a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023</div>

| 85 |

<div align='center'>REGEN BIOPHARMA , INC.

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(unaudited)</div>

|                                       |     | Quarter ended     
 December 31, 2024 |          |   |     | Quarter Ended     
 December 31, 2023 |          |   |
|:--------------------------------------|:----|:------------------|---------:|:--|:----|:------------------|:---------|:--|
| Net Income ( Loss)                    |     | $                 | (515,385 | ) |     | $                 | (144,933 | ) |
| Other Comprehensive Loss:             |     |                   |          |   |     |                   |          |   |
| Unrealized Loss Investment Securities |     |                   |        0 |   |     |                   | (204,847 | ) |
| Comprehensive Loss                    |     | $                 | (515,385 | ) |     | $                 | (349,780 | ) |

<div align='center'>The accompanying Notes are an integral part of these Financial Statements</div>

| 86 |

<div align='center'>REGEN BIOPHARMA , INC.

CONDENSED CONSOLIDATED STATEMENT OF SHAREHOLDERS’ DEFICIT

(unaudited)</div>

| Balance September 30, 2023                  
 Common Shares issued for Cash               
 Unrealized Loss